Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend the trading of its shares (ISIN: FR0005175080) starting November 26, 2025, pending the announcement of the outcome of its capital increase. Trading is expected to resume on November 27, 2025.
Transgene is a biotechnology company focused on developing cancer immunotherapy products. Their flagship candidate, TG4050, has shown clinical promise in head and neck cancer patients. The company also has other viral vector-based candidates in development. With innovative therapies like myvac®, Transgene aims to bring personalized immunotherapy to patients. More information is available on their website.
Investors should note that this press release does not constitute an offer to sell or a solicitation of an offer to buy Transgene’s shares. Restrictions may apply in certain jurisdictions. In France, the offer will be made through a capital increase and a public offering via PrimaryBid. In the European Economic Area, no public offer will be made. In the UK, the information is intended for specific investment professionals. Transgene annonce la suspension de la cotation de ses actions en bourse. Cette suspension est due à une opération financière en cours, et toute invitation à investir est réservée aux personnes habilitées. Aux États-Unis, ce communiqué ne peut être distribué, et les actions de Transgene ne sont pas enregistrées en vertu du U.S. Securities Act. En ce qui concerne la directive MiFID II, les actions de Transgene sont destinées aux contreparties éligibles et aux clients professionnels. Il est important de prendre en compte les restrictions légales et réglementaires avant de prendre une décision d’investissement.
Read more at 1. Apple unveils new iPhone 13 with improved camera and battery life. – CNBC
2. U.S. unemployment rate drops to 5.2% as economy adds 235,000 jobs in August. – Reuters
3. Tesla announces plans to build a new Gigafactory in Texas. – Wall Street Journal
4. Johnson & Johnson’s COVID-19 vaccine receives full FDA approval. – CBS MarketWatch: Transgene annonce la suspension temporaire de